Showing results (11-20 of 219) with videos related to

Sort By:
Pageof 22
Antiviral Therapy|June 9, 2006
A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?Mathew Simcock, Pedram Sendi, Bruno Ledergerber, et al.
Biometrics|July 28, 2016
Dynamic models for estimating the effect of HAART on CD4 in observational studies: Application to the Aquitaine Cohort and the Swiss HIV Cohort StudyMélanie Prague, Daniel Commenges, Jon Michael Gran, et al.
Plos One|September 12, 2013
Cobas ampliprep/cobas TaqMan HIV-1 v2.0 assay: consequences at the cohort levelNinon Taylor, Katharina Grabmeier-Pfistershammer, Alexander Egle, et al.
The Journal of Antimicrobial Chemotherapy|September 9, 2008
Stratification of cumulative antibiograms in hospitals for hospital unit, specimen type, isolate sequence and duration of hospital stayStefan P Kuster, Christian Ruef, Reinhard Zbinden, et al.
Swiss Medical Weekly|July 22, 2010
Risk factors for urinary tract infections due to ciprofloxacin-resistant Escherichia coli in a tertiary care urology department in SwitzerlandJoëlle Nicoletti, Stefan P Kuster, Tullio Sulser, et al.
Statistics in Medicine|July 30, 2011
Analyzing direct and indirect effects of treatment using dynamic path analysis applied to data from the Swiss HIV Cohort StudyKjetil Røysland, Jon Michael Gran, Bruno Ledergerber, et al.
Plos One|November 25, 2010
Different patterns of inappropriate antimicrobial use in surgical and medical units at a tertiary care hospital in Switzerland: a prevalence surveyAlexia Cusini, Silvana K Rampini, Vineeta Bansal, et al.
Journal of Clinical Microbiology|October 14, 2016
Optimal Length of Cultivation Time for Isolation of Propionibacterium acnes in Suspected Bone and Joint Infections Is More than 7 DaysDaniel A Bossard, Bruno Ledergerber, Patrick O Zingg, et al.
BMJ Open|December 3, 2024
Patient-reported outcome measures in an outpatient parenteral antimicrobial therapy program: a prospective cohort studyAndrea R Burch, Bruno Ledergerber, Martin Ringer, et al.
AIDS (London, England)|February 9, 2002
Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV CohortBernard Hirschel, Markus Flepp, Heiner C Bucher, et al.
Pageof 22